Last €14.91 EUR
Change Today +0.20 / 1.36%
Volume 123.1K
AB On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 9:00 AM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

ab science sa (AB) Snapshot

Open
€14.80
Previous Close
€14.71
Day High
€15.00
Day Low
€14.72
52 Week High
02/18/14 - €16.83
52 Week Low
10/16/14 - €7.16
Market Cap
490.9M
Average Volume 10 Days
146.8K
EPS TTM
€-0.47
Shares Outstanding
32.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for AB SCIENCE SA (AB)

Related News

No related news articles were found.

ab science sa (AB) Related Businessweek News

No Related Businessweek News Found

ab science sa (AB) Details

AB Science S.A., a pharmaceutical company, engages in the research, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicines in the United States and Europe. Its lead compound includes Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. It is also pursuing eight on-going phase III studies in human medicine in GIST, metastatic melanoma expressing JM mutation of c-Kit, multiple myeloma, mastocytosis, severe persistent asthma, rheumatoid arthritis, and progressive multiple sclerosis. The company markets its Masitinib under the Masivet brand name for the veterinary market in Europe. Its products are used by hospitals and specialist physicians. AB Science S.A. was founded in 2001 and is headquartered in Paris, France.

112 Employees
Last Reported Date: 08/29/14
Founded in 2001

ab science sa (AB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

ab science sa (AB) Key Developments

AB Science S.A. Recommends the Continuation of Phase 3 Study of Masitinib in Amyotrophic Lateral Sclerosis

AB Science SA announced that the external Data and Safety Monitoring Board (DSMB) has recommended the continuation of its phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) based upon review of the latest safety data. The DSMB was created as part of the company's pivotal clinical study evaluating masitinib in the treatment of amyotrophic lateral sclerosis. The on-going phase 3 clinical trial is an international, multicenter, randomized, double-blind study comparing the efficacy and safety of masitinib with that of placebo in the treatment of patients with amyotrophic lateral sclerosis. Study treatment is given as add-on therapy to patients who have been treated with a stable dose of riluzole. The efficacy analysis is measured by the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-Revised) after 48 weeks of treatment. These results are reassuring because they confirm there are no observed safety concerns with masitinib in combination with riluzole over a 1-year treatment period.

AB Science S.A. Announces Encouraging Follow-Up Results from a Phase 2 Study with its Investigational Drug, masitinib

AB Science S.A. announced encouraging follow-up results from a phase 2 study with its investigational drug, masitinib, in patients with nonresectable, metastatic colorectal cancer after progression to first-line treatment. This was a prospective, multicenter, open label phase 2 study testing masitinib in combination with three standard-of-care chemotherapies including FOLFIRI, FOLFOX, and gemcitabine. Primary endpoint was overall survival (OS) and secondary endpoints included progression-free survival (PFS) and overall response rate (ORR). AB Science has previously reported a survival benefit for masitinib plus FOLFIRI (irinotecan, 5-fluorouracil and folinic acid) in this indication based on preliminary data analysis with a median OS of 14.5 months. One year later, after a median follow-up of approximately 23 months, this survival benefit has been confirmed with a median OS of 18.0 months. Of note, approximately 50% of the masitinib plus FOLFIRI treatment cohort were positive for the KRAS mutation. These results compare favorably to published results for second-line FOLFIRI treatment in which median OS was reported as 12.5 months in patients with wild-type KRAS and 11.1 months in patients with mutant KRAS. The survival endpoints of PFS and ORR were also favorable for masitinib plus FOLFIRI when compared with historic benchmarks, regardless of KRAS mutation status. In the overall study population, median PFS was 6.2 months as compared with 3.9 to 4.9 months for the FOLFIRI benchmark, and ORR was 28% as compared with 10% to 14% for the FOLFIRI benchmark. Of significance, one patient reported a confirmed complete response, which is an exceptional observation in this clinical setting. Safety data showed that the combination of masitinib and FOLFIRI has an acceptable safety profile. The decision to move to the currently recruiting phase 3 study was based on encouraging preliminary results from phase 2, a decision that is corroborated by these follow-up data.

AB Science S.A. Presents at Oddo Midcap Forum, Jan-08-2015

AB Science S.A. Presents at Oddo Midcap Forum, Jan-08-2015 . Venue: Lyon’s Convention Center, Lyon, France.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AB:FP €14.91 EUR +0.20

AB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AB.
View Industry Companies
 

Industry Analysis

AB

Industry Average

Valuation AB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 202.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 177.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AB SCIENCE SA, please visit www.ab-science.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.